Literature DB >> 29160648

[Infection by the Epstein-Barr virus between the years 2006-2015 in the health area of Santiago de Compostela. Relationship with age and sex].

R Trastoy Pena, J J Costa Alcalde1, J Rodríguez Calviño, D Navarro de la Cruz, G Barbeito Castiñeiras, A Aguilera Guirao.   

Abstract

OBJECTIVE: In Spain, the age and sex to which the primary infection by EBV is produced is poorly studied. The objective of this work is to know its relation with the presence of the primary infection by EBV between the years 2006 and 2015 in our health area.
METHODS: From the Santiago de Compostela health area between 2006 and 2015, 578 patients with serological patterns of EBV primoinfection were selected. This patients presented serological results of IgM-VCA positive, IgG-VCA positive and EBNA negative.
RESULTS: We found 260/578 (45%) adolescents (11- 19 years). In the number of cases by age the maximum was observed, at 2 and 16 years. Between 14-19 years, 62% (79/127) of women between 14-16 years of age, median age 15.8 years (IQ: 14.8-16.4) compared to 48% (49/102) of men, median age 16 years (IQ: 15.7-16.6) (p = 0.032, p = 0.02, respectively).
CONCLUSIONS: As in our study, in the developed countries the majority of primary infections by EBV occur in adolescence and a bimodal distribution is observed in relation to age. During adolescence women acquire before men the first infection by EBV.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29160648

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  2 in total

1.  Increasing Epstein-Barr virus infection in Chinese children: A single institutional based retrospective study.

Authors:  Kiran Devkota; Maio He; Meng Yi Liu; Yan Li; You Wei Zhang
Journal:  F1000Res       Date:  2018-08-07

2.  Molecular characterization of Epstein-Barr virus variants detected in the oral cavity of adolescents in Cali, Colombia

Authors:  Daniela Arturo-Terranova; Sebastián Giraldo-Ocampo; Andrés Castillo
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.